Ibrutinib (Imbruvica): A novel targeted therapy for chronic lymphocytic leukemia

P and T

Volumn 39, Issue 7, 2014, Pages

  Parmar, Sapna ^a   Patel, Khilna ^b   Pinilla Ibarz, Javier ^c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; BREAKPOINT CLUSTER REGION PROTEIN; BRUTON TYROSINE KINASE; CARBAMAZEPINE; CHLORAMBUCIL; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FLUDARABINE; HYPERICUM PERFORATUM EXTRACT; IBRUTINIB; ITRACONAZOLE; KETOCONAZOLE; OFATUMUMAB; PHENYTOIN; POSACONAZOLE; PROTEIN TYROSINE KINASE; RIFAMPICIN; RITUXIMAB; TELITHROMYCIN; VORICONAZOLE;

CHRONIC LYMPHATIC LEUKEMIA; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; FOOD DRUG INTERACTION; GERIATRICS; HUMAN; KIDNEY FAILURE; LACTATION; LIVER FAILURE; MULTICENTER STUDY (TOPIC); NONHUMAN; NOTE; PEDIATRICS; PHARMACODYNAMICS; PHARMACY AND THERAPEUTICS COMMITTEE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOXICITY;

EID: 84904416422     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (19)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid 2013;8:37-45.
3. Gribben JG. How I treat CLL up front. Blood 2010;115:187-197.
4. Slager SL, Kay NE. Familial CLL: What does it mean to me? Clin Lymphoma Myeloma 2009;9(Suppl 3):S194-S197.
5. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004;2004:163-183.
6. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia. Blood 2008;111:5446-5456.
7. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukemia. Br Med Bull 2008;87:49-62.
8. Byrd JC, Furman RR, Coutre SE, et al. Targeting Btk with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
9. Bhatt V, Alejandro L, Michael A, et al. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy 2014;34:303-314.
10. Imbruvica [package insert]. Sunnyvale, California: Pharmacyclics, Inc.; February 2014.
11. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013;34:592-601.
12. Khan WN. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 2001;23:147-156.
13. Aalipour A, Advani RH. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013;163:436-443.
14. Herman SE, Gordon AL, Hertlein E, et al. Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-6296.
15. Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel Btk inhibitors in clinical development. J Hematol Oncol 2013;6:59.
16. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B cell malignancies. J Clin Oncol 2013;31:88-94.
17. Sukbuntherng J, Jejurkar P, Chan S, et al. Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL) [abstract 7056]. J Clin Oncol 2013;31.
18. Pharmacyclics, Inc. A phase 3 study of ibrutinib versus ofatumumab in patients with relapsed or refractory CLL (RESONATE). In: ClinicalTrials. gov. Bethesda, Maryland: U.S. National Library of Medicine. 2014. Available at: http://clinicaltrials. gov/show/NCT01578707. Accessed March 8, 2014.
19. Red Book Online. Ann Arbor, Michigan: Truven Health Analytics. Available at: www.micromedexsolutions.com. Accessed June 5, 2014.